A Raleigh-based non-profit subsidiary of the Foundation Fighting Blindness, The Retinal Degeneration Fund, launched a new patient-focused gene therapy company that will also be based in Raleigh. The company is Opus Genetics, and according to a statement, it will develop “therapies for orphan inherited retinal diseases.” It is backed by $19 million in seed funding from the Retinal Degeneration Fund, the Manning Family Foundation, and Bios Partners.
